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Background. In our previous study we reported the synthesis and cytotoxicity of two trans-platinum(II) complexes: 
trans-[PtCl2(3-acetylpyridine)2] (1) and trans-[PtCl2(4-acetylpyridine)2] (2), revealing significant cytotoxic potential of 
2. In order to evaluate the mechanism underlying biological activity of both trans-Pt(II) isomers, comparative studies 
versus cisplatin were performed in HeLa, MRC-5 and MS1 cells.
Materials and methods. The cytotoxic activity of the investigated complexes was determined using SRB assay. The 
colagenolytic activity was determined using gelatin zymography, while the effect of platinum complexes on matrix 
metalloproteinases 2 and 9 mRNA expression was evaluated by quantitative real-time PCR. Apoptotic potential and 
cell cycle alterations were determined by FACS analyses. Western blot analysis was used to evaluate the effect on 
expression of DNA-repair enzyme ERCC1, and quantitative real-time PCR was used for the ERCC1 mRNA expression 
analysis. In vitro antiangiogenic potential was determined by tube formation assay. Platinum content in intracellular 
DNA and proteins was determined by inductively coupled plasma-optical emission spectrometry. 
Results. Compound 2 displayed an apparent cytoselective profile, and flow cytometry analysis in HeLa cells indicat-
ed that 2 exerted antiproliferative effect through apoptosis induction, while 1 induced both apoptosis and necrosis. 
Action of 1 and 2, as analyzed by quantitative real-time PCR and Western blot, was associated with down-regulation 
of ERCC1. Both trans-complexes inhibited MMP-9 mRNA expression in HeLa, while 2 significantly abrogated in vitro 
tubulogenesis in MS1 cells. 
Conclusions. The ability of 2 to induce multiple and selective in vitro cytotoxic effects encourages further investiga-
tions of trans-platinum(II) complexes with substituted pyridines. 
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Introduction 
Cisplatin (CDDP) represents the basis of combi-
nation chemotherapy regimens in solid tumors, 
although main drawbacks to its successful ap-
plication are development of resistance and toxic 
side effects.1,2 Search for CDDP analogues with 
improved pharmacological properties by manipu-
lation of the structure of ligands, has achieved a 
reduction in toxicity, but obtained limited success 
in broadening spectrum of activity.3-5 However, 
novel classes of platinum complexes including 
trans-Pt(II) compounds with planar amine ligands 
are able to exert cytotoxicity, equivalent or better 
to that of CDDP, and posses different mechanisms 
of antitumor action.6-10 Cytotoxicity data of 107 
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platinum compounds from the NCI human tumor 
panel recognized trans-platinum complexes, of 
structural formula [PtCl2(L)(L’)] with planar amine 
ligands (L and L’ may be the same or different), as 
unique group of trans-platinum drugs that had cy-
totoxicities similar to that of their cis-isomers and 
CDDP, and possessed a novel cytotoxicity pro-
file.11 Search for new platinum compounds with 
the complementary or wider range of activity than 
CDDP, whose actions would be more selective to-
ward cancer comparing to normal cells, and which 
would possess different targets than the traditional 
CDDP, is always attractive topic.7 Formation and 
persistence of DNA-adducts are considered vital 
in platinum drug induced cytotoxicity, and type 
of DNA-damage is determined by the nature of 
platinum-coordinating ligands.4,12,13 However, cel-
lular sensitivity to platinum complexes is multifac-
torial, with some of major mechanisms being the 
proficiency of the cellular mechanism for adducts 
recognition and repair, and the ability of cells to 
reduce intracellular platinum, due to deactivation 
by sulphur-containing biomolecules and/or drug 
efflux.14-16 Numerous studies imply the significance 
of copper transporters in regulating cellular phar-
macology of CDDP by mediating its uptake and ef-
flux in different cell lines.17
Structure-activity studies up to date demon-
strated that bulky amine carrier ligands, such as 
pyridine, appear to sterically hinder approach of 
incoming nucleophiles to the axial positions of the 
platinum center, thus reducing deactivation of plat-
inum by sulphur-containing biomolecules.18 Trans-
orientation of planar pyridines seems to contribute 
to greater affinity of complexes for interstrand 
cross-link formation and DNA conformational dis-
tortion, comparing to cis-isomers, leading to activa-
tion of different DNA-repair mechanisms.19-21 
Recent studies demonstrated that fine tuning of 
the biological activity of trans-platinum pyridines 
may be achieved by different positioning of the 
substituents such as: methyl-group and 3- or 4-hy-
droxymethyl-group, on the pyridine ring.19,20,22   
In our previous investigations, we have synthe-
sized and characterized two trans-platinum(II) com-
plexes, of structural formula trans-[PtCl2(L)2] with 
substituted pyridine ligands, L=n-acetylpyridine, 
(n = 3 or 4) (Figure 1). Cytotoxicity evaluation on the 
panel of tumor cell lines revealed potential of trans-
[PtCl2(4-acetylpyridine)2] to exert activity in low 
micromolar range, with the highest cytotoxicity in 
HeLa cells, comparable to that of CDDP.23 Aim of 
this study was to investigate the molecular mecha-
nisms underlying the in vitro biological activity of 
trans-[PtCl2(4-acetylpyridine)2] (complex 2) and 
its less cytotoxic structural isomer trans-[PtCl2(3-
acetylpyridine)2] (complex 1), and to understand 
possible relations to their structural characteristics, 
such as the position of the acetyl substituent on the 
pyridine ring. Mechanistic studies were performed 
in comparison to CDDP in human cervix carcinoma 
cell line (HeLa), and two other cell lines: human 
normal lung fibroblast (MRC-5) cell line, which was 
used as a non-cancerous model system for in vitro 
toxicity evaluation, and murine endothelial cells 
immortalized by infection with a retrovirus encod-
ing SV40 large T antigen (MS1), as a model system 
for in vitro testing of antiangiogenic effect.24 In or-
der to test if the cytotoxic responses produced by 
compounds 1 and 2 in HeLa cells correlated with 
the platinum content in cellular DNA and to evalu-
ate the mechanism of cytotoxic action, we studied 
the ability of complexes to bind intracellular DNA 
and proteins, and to induce DNA-damage related 
response, cell cycle alterations and apoptosis.
Based on the literature data reporting inhibitory 
effect of some platinum(II) compounds on matrix 
metalloproteinases (MMP) activity, we assumed 
that trans-[PtCl2(n-acetylpyridine)2] (n = 3 or 4), 
may possess ability to modulate diverse cellular 
processes, including those related to the cancer cell 
angiogenic and metastatic behaviour.25-27 Thus, in 
the final part of our study, we analyzed if the tested 
FIGURE 1. Structures of the investigated trans-platinum(II) complexes: 
trans-[PtCl2(3-acetylpyridine)2] 1; trans-[PtCl2(4-acetylpyridine)2] 2.
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complexes affected gelatinolitic activity and mRNA 
expression of secreted forms of MMP-2 and MMP-
9, or abrogated process of angiogenesis in vitro.
Materials and methods
Synthesis
Platinum complexes trans-[PtCl2(3-acetylpyridine)2] 
(complex 1) and trans-[PtCl2(4-acetylpyridine)2] 
(complex 2) (Figure 1) were synthesized and charac-
terized by IR and NMR, as previously described.23  
Cytotoxic activity
Cell culture
HeLa and MRC-5 cells cells were maintained as 
monolayer culture in nutrient medium, Roswell 
Park Memorial Institute 1640 medium (RPMI1640), 
(Sigma-Aldrich Co).28 MS1 cells were maintained as 
monolayer culture in nutrient medium, Dulbecco`s 
Modified Eagle Medium (DMEM), (Sigma-Aldrich 
Co). Nutrient medium conditions and cell mainte-
nance procedures were explained previously.29
In vitro cytotoxicity assay (SRB)   
Cells were seeded into 96-well plates (Thermo 
Scientific Nunc™), in number of 7000 cells per well 
(c/w) for MS1 and 5000 cells per well for MRC-5, 
and left for 24 h before complexes 1, 2 and CDDP 
were added. Preparation of test solutions was 
performed immediately before experiments by 
dissolving in DMSO. The cells were treated with 
serial dilutions of the studied compounds for 48 
h. Final concentrations achieved per wells were 1 
μM, 3 μM, 10 μM, 30 μM and 100 μM. Each con-
centration was tested in triplicates, and the final 
concentration of DMSO solvent never exceeded 
0.33%. Cytotoxicity of the investigated platinum 
complexes, and CDDP as a referent compound, 
was evaluated after 48 h of continuous action, us-
ing sulforhodamine B (Sigma–Aldrich Co.) colori-
metric assay.30 The percentages of surviving cells 
relative to untreated controls were determined. 
The IC50 value, defined as the concentrations of the 
compound causing 50% cell growth inhibition, was 
estimated from the dose-response curves.
Flow cytometric analysis of cell cycle 
phase distribution
Quantitative analysis of cell cycle phase distribu-
tion was performed by flow-cytometric analysis of 
the DNA content in fixed HeLa cells, after stain-
ing with propidium iodide (PI).31 Cells were seed-
ed at density of 2x105 into 6-well plates (Thermo 
Scientific Nunc™), and grown in nutrient medium. 
After 24 h cells were exposed to the investigated 
compounds 1, 2 and CDDP for 24 h,  at concen-
trations corresponding to IC50 or 1.5xIC50. The de-
tailed procedure was previously described.29 Cell 
cycle phase distribution was analyzed using a 
fluorescence activated cell sorting (FACS) Calibur 
Becton Dickinson flow cytometer and Cell Quest 
computer software.
Statistical analysis
Calculations of mean, SD, and p values were per-
formed on triplicate experiments. The Student t-
test was used to calculate p-values for comparison. 
The significant statistics was set at a p-value <0.05 
(Stata Software).
Annexin V-FITC apoptotic assay 
Quantitative analysis of apoptotic and necrotic cell 
death induced by the investigated platinum com-
plexes and CDDP, as a referent compound, was 
performed by Annexin V-FITC apoptosis detection 
kit, according to the manufacturer’s instructions 
(BD Biosciences). Precisely, 2x105 HeLa cells treat-
ed with 1xIC50 of the tested compounds and CDDP 
for 4 and 24 h and the analysis was performed as 
previously reported.29
Measurement of platinum binding to 
intracellular DNA or proteins using 
ICP-OES 
Binding of platinum(II) to cellular DNA and pro-
teins was analyzed in HeLa cells, using inductively 
coupled plasma optical emission spectrometry 
(ICP-OES). 6x106 cells were seeded into 75 cm2 
dish (Thermo Scientific Nunc™) and treated with 
the investigated complexes in concentrations cor-
responding to 0.5xIC50. Following 6 or 24 h, cells 
were harvested by scraping, washed by ice cold 
PBS and cell pellet was collected by centrifuga-
tion at 2000 rpm, 10 min. DNA and proteins were 
isolated using TRI Reagent® (Sigma-Aldrich Co.) 
according to the manufacturer’s procedure and 
concentrations were determined spectrophoto-
metrically by measuring absorbance at A260 and 
A280 nm respectively (Eppendorf BioPhotometer 
6131). Platinum(II) levels were determined in iso-
lated DNA and protein fractions according to the 
standard procedure, using Thermo Scientific iCAP 
6500 Duo ICP (Thermo Fisher Scientific).
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Quantitative real-time PCR (qRT-PCR)
Sample preparation for qRT-PCR; RNA extraction 
and cDNA synthesis 
6x106 HeLa cells were seeded in nutrient medium 
and after 24 h  treated with the investigated com-
plexes 1, 2 or CDDP at concentrations correspond-
ing to 0.5xIC50, for 6 and 24 hours. After treatment, 
cells were washed with ice cold PBS and harvest-
ed by scraping, while cell pellet was collected by 
centrifugation. Total RNA was isolated using TRI 
Reagent® (Sigma-Aldrich Co.) according to manu-
facturer’s recommendations. RNA extraction in 
details and cDNA synthesis were described ear-
lier.29
Quantitative real-time PCR 
The analysis of gene expression level of several genes 
and GAPDH (endogenous control) was done by us-
ing TaqMan® Gene Expression Assays for human 
genes (assay ID Applied Biosystem, listed as follow-
ing: Hs_01012155_g1 (ERCC1); Hs_01548727_m1 
(MMP-2);  Hs_00234579_m (MMP-9); Hs_00355782_
m1 (GAPDH)) on ABI PRISM® 7500 PCR instru-
ment (Applied Biosystems). PCR was performed as 
previously reported.29
Western blot
HeLa cells were treated with the investigated 
platinum complexes 1 and 2 or CDDP for 6 h, at 
concentrations corresponding to the 0.5xIC50 val-
ues obtained for 48 h of continuous treatment. 
Cells maintained in nutrient medium were used 
as the untreated control. Sample preparation and 
the analysis were performed as described in the 
previous study.29,32 Purified mouse anti-human 
ERCC1 monoclonal antibody (1:500 dilution) (BD 
Biosciences Pharmingen) was used, as well as the 
secondary anti-mouse IgG-peroxidase conjugated 
antibody (1:2000 dilution) (Sigma-Aldrich Co.).
Gelatin zymography
Effect of the investigated trans-Pt(II) complexes 
and CDDP on gelatinolitic activity of secreted 
matrix metalloproteinases MMP-2 and MMP-9 in 
HeLa was analyzed by zymography in 10% SDS-
polyacrylamide gels impregnated with 0.1% gela-
tin.33 HeLa cells were treated with the complexes 
(0.5xIC50) for 6 h in serum-free medium and the 
precise conditions, as well as the procedure have 
been given previously.29 The gelatinolytic activities 
were visualized as clear transparent bands against 
the blue background of Coomassie brilliant blue-
stained gelatin.
Tube formation assay (in vitro 
angiogenesis assay) 
Potential of trans-platinum(II) complexes and 
CDDP to inhibit angiogenesis in vitro was analyzed 
by tube formation assay in MS1 cells. MS1 cells, 
when plated into gel of basement membrane pro-
teins, rapidly organize into multicellular tube-like 
structures, while antiangiogenic effect of the tested 
compounds is observed as the reduction of tube 
formation.24 Briefly, 24-well plates were coated 
with collagen and allowed to solidify at 37°C 1 h. 
MS1 cells were seeded into wells (1x105 c/w) in nu-
trient medium. Complexes 1 and 2 were added 2 h 
after cells settled, at concentrations corresponding 
to 0.03xIC50, which was non-toxic to the cells. Tube 
formation was observed periodically over time un-
der microscope and representative pictures were 
A
B
FIGURE 2. A Diagram presenting cytotoxicity of the tested agents and cisplatin 
in terms of IC50 values, obtained for 48 h of drug action, by SRB assay. IC50 values 
present average (±SD) obtained from three or more independent experiments. 
Asterisks denotes p values, when comparing MRC-5 cells to HeLa cells, by ANOVA 
test: 1 (*) p > 0.05; 2 (**) p < 0.001; CDDP (*) p > 0.05; B Micrographs of HeLa cells 
or MRC-5 cells exposed to equimolar (5 mM) concentration of tested platinum 
complexes 1, 2 or CDDP, following 24 h treatment, versus control (non treated 
cells). Micrographs are one representative experiment selected of three and were 
obtained with Olympus digital camera connected to the inverted microscope (Carl 
Zeiss, Jena, Germany, objective 6.3/0.20).
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taken after 24 h incubation with Olympus digital 
camera connected to the inverted microscope (Carl 
Zeiss, Jena, Germany, objective 6.3/0.20).
Morphological examination by light 
microscopy
HeLa cells (50000 c/w) and MRC-5 cells (125000 
c/w), were seeded into 6-well plates (Thermo 
Scientific Nunc™), in the corresponding nutrient 
medium, and after 24 h of growth cells were ex-
posed to complexes 1, 2 or CDDP, at equimolar con-
centrations of 5 mM. Following 24 h of treatment, 
cells were observed under the light microscope 
and photographs were taken with Olympus digital 
camera connected to the inverted microscope (Carl 
Zeiss, Jena, Germany, objective 6.3/0.20)..  
Statistical analysis
Statistical comparison of IC50 values in MRC-5 cell 
line versus HeLa and MS1 cell line, was performed 
using one way statistical analysis of variance (one-
way ANOVA - GraphPad Software). IC50 values 
were determined as mean ± SD (standard devia-
tion) of three or more independent experiments.  
Results
In vitro cytotoxicity assay (SRB)
In order to further investigate cytotoxic and cy-
toselective potential of the two trans-platinum iso-
mers, in comparison to CDDP, growth inhibitory 
study was performed in MRC-5 cells, which were 
used as non-cancerous model for in vitro toxicity 
evaluation; and MS1 cells as in vitro model for test-
ing of antiangiogenic effect. Cytotoxicity of the 
complexes summarized in terms of IC50 values, is 
presented in Figure 2A. IC50 values (mM) obtained 
for 48 h of continuous drug action in MRC-5 cells, 
may be arranged in increasing order as following: 
15.4 ± 3.1 mM, for CDDP; 40.0 ± 11.1 mM for com-
plex 1; and 56.4 ± 5.0 mM for 2, indicating lower 
toxicity of trans-complexes in non-cancerous cell 
model comparing to CDDP. Particularly, complex 
2 exerted less cytotoxicity in MRC-5 cells than in 
HeLa, by a factor of approximately four-fold, in-
dicating significant cytoselective potential toward 
neoplastic cells (p < 0.001). Both trans-complexes 
exhibited poor activity, in MS1 cells with IC50 val-
ues being: 76.3 ± 0.5 mM for complex 2; 34.5 ± 7.8 
mM for complex 1; comparing to CDDP (IC50 18.6 
± 5.4 mM). 
Morphological examination
The results of the morphological analysis of HeLa 
and MRC-5 cells are presented in Figure 2B, as mi-
crographs obtained following 24 h agents action. 
Results indicated that in the presence of 5 mM of 
complex 2, concentration which corresponded to 
IC50 value in HeLa cells, viability of MRC-5 cells was 
not significantly altered, suggesting cytoselective 
potential toward neoplastic HeLa cells. Oppositely, 
complex 1 haven’t exerted cytoselective potential, 
as observed in Figure 2B. Morphological changes 
of MRC-5 cells, such as: cell shrinkage and detach-
ment, following equimolar treatment with CDDP, 
were indicative for apoptosis. 
Determination of cell cycle perturbation 
by flow cytometry
The potential of the tested complexes to induce cell 
cycle alterations in comparison to CDDP in HeLa 
cells, was examined by flow cytometry using stain-
ing with PI. Results are presented as diagrams of 
A
B
FIGURE 3. Diagrams presenting cell cycle phase distribution of treated HeLa cells, 
obtained by flow-cytometric analysis of the DNA content in fixed cells, after staining 
with PI. HeLa cells were collected following 24 h treatment with tested complexes 
or cisplatin at concentration corresponding to A IC50 and B 1.5xIC50. Bar graphs 
represent mean ± SD in at least three independent experiments. Asteriks (*) denotes 
p values < 0.05, calculated by Student t-test, indicating statisticaly significant 
differences (Stata Software). 
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cell distribution over the cell cycle phases after 24 
h of agent action, where Figure 3A shows effects 
of the complexes at concentration corresponding 
to IC50, and Figure 3B shows effects of the com-
plexes at concentration corresponding to 1.5xIC50. 
Complex 1, induced arrest in the S phase of cell 
cycle at concentrations corresponding to 1.5 x 
IC50, but less than CDDP (Figure 3B). Complex 1 
induced decrease of cell percentage in the G0/G1 
phase in concentration dependent manner, com-
paring to the non-treated control. CDDP induced 
dose-dependent arrest in the S phase of cell cycle, 
and decrease of cell progression through G2/M 
phase (Figures 3A and 3B).
The Student t-test showed that the difference is 
considered to be statisticaly significant only for G0/
G1 cells when two groups of cell cycle results were 
compared (control cells compared to cells treated 
with 1.5xIC50. complex 1, and control cells com-
pared to cells treated with 1.5xIC50. CDDP (p<0.05, 
Stata Software)).
Quantification of apoptosis by annexin 
V-FITC binding
Potential of the investigated complex to induce 
apoptosis in HeLa cells was assessed by flow cy-
tometry using Annexin V-FITC and PI dual stain-
ing. Dot plots are presented in Figure 4A, while 
Figure 4B reports the results of a representative ex-
periment as percentages of apoptotic cells (Annexin 
V-FITC positive and PI negative) and necrotic cells 
(Annexin V-FITC negative and PI positive) meas-
ured periodically at 4 and 24 h. Data obtained indi-
cated that complex 2 caused 15.5% of apoptosis in 
HeLa cells following 24 h of action, while the per-
A
B
FIGURE 4. A Dot plot diagrams obtained by flow-cytometric 
analysis of treated HeLa cells after dual staining with Annexin 
V-FITC and PI. Annexin V-FITC/PI staining was monitored 
overtime, following 4 and 24 hours in HeLa cells exposed to 
complex 1, 2 or CDDP at concentrations corresponding to IC50. 
Representative dot plots of three independent experiments are 
given, presenting intact cells at lower-left quadrant, FITC(-)/
PI(-); early apoptotic cells at lower-right quadrant, FITC(+)/
PI(-); late apoptotic or necrotic cells at upper-right quadrant, 
FITC(+)/PI(+); and necrotic cells at upper-left quadrant, FITC(-)/
PI(+). B Apoptosis and necrosis were quanitified by FACS after 
Annexin V-FITC and PI labeling; bar graphs represent mean ± 
SD in at least three independent experiments.
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centage of necrotic cells was negligible. Kinetics, 
as well as the degree of apoptosis induction, was 
comparable to CDDP. Complex 1 at concentration 
of IC50 initiated early apoptotic cell death after 4 
and 24 h action, where apoptotic cell population 
represented 14.2% and 15.5% of total cells, respec-
tively. Though, after 24 h of action more than 50% 
of total cell population underwent cell death in ei-
ther apoptotic or necrotic manner. 
Determination of the platinum(II) 
binding to intracellular DNA and proteins 
Intracellular platinum(II) distribution among DNA 
and protein fractions in HeLa cells treated with eq-
uitoxic concentrations of investigated complexes 
for 6 and 24 h, was analyzed using ICP-OES analy-
sis, and results are presented in Figure 5. Levels 
of platinum(II)-DNA binding (Figure 5A), varied 
between the investigated complexes, especially 
following short-term (6 h) treatment, when plati-
num content (pg Pt/mg DNA) decreased in order: 
21 ± 2.5  (complex 1); 14.5 ±0.4 (CDDP) and 6.4±1.1 
(complex 2). Both CDDP and 1 seemed to be more 
effcient in promoting cellular DNA binding com-
paring to complex 2, though differences in double-
stranded DNA platination affinity between com-
plex 2 and CDDP were in accordance to the recent 
study.34 Platinum(II)-DNA content, decreased in 
time-dependent manner, and reached comparable 
levels following 24 h of action. Results of the ICP-
OES analysis of platinum(II) content in the protein 
fraction (Figure 5B), indicated that 1 exhibited the 
highest affinity for protein binding following both 
6 h and 24 h treatment, while 2 exhibited the lowest 
binding affinity. Time dependent decrease of pro-
tein binding, indicated reversible nature of interac-
tions of 1 and 2, oppositely to CDDP.
Protein and mRNA expression of ERCC1 
DNA excision repair protein ERCC1 is an important 
component of NER (Nucleotide Excision Repair) 
which is primarily induced in the repair of bulky 
platinum-DNA adducts.35 In order to evaluate 
whether investigated complexes induce ERCC1-
dependent cell response as the result of cytotoxic 
DNA lesions, we investigated mRNA and protein 
expression level of ERCC1. Data obtained on HeLa 
cells after 6 h of continuous treatment with equi-
toxic concentrations of tested trans-platinum com-
plexes or CDDP indicated negative modulation of 
ERCC1 expression on both mRNA and protein lev-
els (results presented in Figure 6). Complexes 1, 2 
and CDDP decreased ERCC1 mRNA level for 45%, 
40% and 36%, respectively, comparing to the non 
treated control (Figure 6A). Western blot analysis 
(Figure 6B) showed reduction of ERCC1 protein 
levels, following both trans-complexes 1 and 2 ac-
tion, while there were no obvious changes associ-
ated with CDDP treatment.
Tube formation assay (in vitro 
angiogenesis assay)
In order to determine the potency of the investigat-
ed complexes to restrict the angiogenesis of cancer 
cells, we performed an in vitro tube formation assay 
in mouse endothelial cells MS1. In our experiment, 
MS1 endothelial cells were treated with sub-toxic 
concentrations of the investigated complexes in or-
A
B
FIGURE 5. Diagrams presenting quantitative determination of platinum(II) content in 
DNA and proteins in HeLa cells, obtained by  ICP-OES analysis, following 6 h and 24 
h of action of 1, 2 or CDDP; A Platinum content in cellular DNA; B Platinum content 
in cellular protein fraction (pg Pt/mg proteins). Bar graph represent mean ± SD of 
three independent experiments. 
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der to distinguish among growth inhibitory effect 
and their potential to inhibit the formation of tube-
like structures. Antiangiogenic effect was observed 
for both tested trans-platinum complexes, and re-
sults are presented in Figure 7A. Trans-complexes, 
particularly complex 2, showed inhibitory effect 
on the formation of cell-cell contact and tube-like 
structures, at very low sub-toxic concentration cor-
responding to 0.03xIC50, while CDDP did not ex-
hibit any significant effect in this assay. 
Gelatin zymography and determination 
of MMP-9 and MMP-2 expression on 
mRNA level
We investigated whether tested complexes were 
able to modulate mRNA expression of MMP-2 and 
MMP-9 or affect their gelatinolitic activity in vitro. 
The effect of 1 and 2 on the activity of the secreted 
forms of MMP-2 and MMP-9 in HeLa cells, was 
examined following 6 h action, by gelatin zymog-
raphy and the results are presented in Figure 7B. 
Quantitative analysis of the gelatin zymography 
was performed by Image J software, and is present-
ed in Figure 7B. Results obtained indicated that 
complex 1 induced moderate decrease of gelati-
nolitic activity of MMP-2 and MMP-9 in compari-
son to the control (non treated cells), when applied 
at concentration of 0.5xIC50, (Figure 7C). CDDP 
failed to show effect in this assay, while complex 2 
induced minor enhancement of metalloproteinases 
activity. Results obtained by qRT-PCR indicated 
that trans-complexes reduced level of MMP-9 mR-
NA, comparing to the control, following 6 h treat-
ment (Figure 7D). Complex 2 and CDDP, when ap-
plied at equitoxic concentrations corresponding to 
0.5xIC50, upregulated MMP-2 mRNA, while com-
plex 1 did not induce obvious alteration of MMP-2 
mRNA expression. 
Discussion
In our previous study we have reported synthesis, 
structural characterization and cytotoxic potential 
of two trans-platinum complexes of structural for-
mula trans-[PtCl2(n-acetylpyridine)2] (n = 3 or 4, 
complex 1 or 2, respectively), revealing significant 
cytotoxic potential of complex 2 on several tumor 
cell lines, with the highest potential in HeLa cells.23 
In the current study we investigated the mecha-
nism underlying in vitro antitumor activity of both 
isomers, in order to understand possible relations 
to their structural differences, such as position of 
the acetyl substituent on pyridine ligand. Study 
was performed in comparison to CDDP as referent 
compound. 
Cytotoxicity evaluation in MRC-5 cells, which 
were used as in vitro non-cancerous cell model, 
showed feature of the tested trans-platinum iso-
mers to exert less toxicity in MRC-5, than in HeLa. 
Particularly complex 2 with 4-acetylpyridine, ex-
hibited significant cytoselective potential toward 
neoplastic cells (HeLa) relative to normal cells 
(MRC-5), cells (p < 0.001), comparing to CDDP (p 
> 0.05). 
According to the results of flow cytometry, an-
tiproliferative action of complex 1, was associated 
to minor cell cycle arrest in the G0/G1 and S phase, 
and consequent initiation of cell death. When 
tested at equitoxic concentrations (IC50), complex 
1 induced significant percentage of necrotic cells, 
comparing to complex 2 and CDDP, observed al-
ready after 4 h of action. Complex 2 exhibited the 
rate and kinetics of apoptosis induction similar to 
that of CDDP.
Mechanism of anticancer activity of platinum 
drugs is believed to be associated with their bind-
ing with cellular DNA. The level of DNA-binding 
A
B
FIGURE 6. A Results of the qRT-PCR analysis of ERCC1 mRNA presented as diagrams 
showing relative expression level of ERCC1 mRNA, normalized with the GAPDH; Bar 
graph represent mean ± SD of three independent experiments; B Protein expression 
levels of ERCC1 determined by Western blot, and normalized with b-actin. Tested 
agents 1, 2 and CDDP were applied at concentration of 0.5xIC50. Western blot results 
show one representative experiment selected of three.
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is considered to provide more meaningful informa-
tion (related to activity) than total cellular uptake 
especially as platinum drugs may undergo compl-
exation with cellular platinophiles, so that only a 
very small fraction of the drugs actually binds with 
DNA.36
The results of the present work, demonstrat-
ing nuclear DNA binding affinity of compounds 1 
and 2, are consistent with the hypothesis that the 
minor structural modifications of carrier ligands 
in trans-mononuclear platinum complexes could 
modulate the DNA binding afinity, resulting in 
the altered biological (pharmacological) activity 
of these new platinum complexes in tumor cells, 
relative to CDDP.37 Results of the analysis of the 
actual platination of DNA, presented in terms of 
pg Pt/mg DNA, showed that 2 exhibited the lowest 
DNA binding following 6 h treatment, with plati-
num content being less by a factor of approximately 
threefold comparing to 1, though reaching similar 
level of DNA binding as 1 and CDDP following 24 
h treatment. Structure-activity correlation suggests 
that the acetyl-group in the para-position on the 
planar pyridine rings (4-acetylpyridine) in complex 
2, may additionaly hamper positioning of the non-
leaving moieties in the adducts of this analogue, 
that would be entirely favorable for its interaction 
with the double helix.37 It should be noted that com-
plex 2 platinum-DNA level just slightly decreased 
during 24 h treatment comparing to complex 1 and 
A
B
FIGURE 7. A Micrographs of tube formation of MS1 cells, taken following 
24 h treatment with sub-toxic concentrations (0.03xIC50) of complexes 
1, 2 or CDDP, or without treatment (control cells); B Results of the 
gelatin zymography following 6 h treatment with 0.5xIC50 of 1, 2 or 
CDDP. Supernatants were collected and equal amounts of proteins 
were analysed by zymography. Representative of three independent 
experiments; C Diagram presenting quantification of catalytic activity 
of secreted MMP-2 and MMP-9 in treated HeLa cells, obtained by 
quantitative analysis of zymograms, using Image J software. Data 
are expressed in arbitrary units as mean ± standard deviation of three 
independent experiments; D Results of the qRT-PCR analysis of the MMP-
2 and MMP-9 mRNA expression level in HeLa cells after 6 h treatment 
with 1, 2 or CDDP, at concentration 0.5xIC50. Each bar represents the 
average (±SD) of three independent experiments.
C
D
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CDDP, suggesting on the other side sustainable na-
ture of platinum-DNA lesion. Different studies sup-
port the assumption that long-lived DNA-adducts, 
formed by mononuclear trans-platinum(II) com-
plexes containing planar ligands such as quinoline 
or pyridine constitute potential cytotoxic lesions.38 
The higher cytotoxicity of 2 comparing to 1, may 
be attributed to its ability to form different DNA 
conformational distorsions and lesions which are 
differentially processed by DNA damage recogni-
tion/repair proteins, and to the ability of compound 
to induce different cellular response.21 Lower level 
of unfavorable interactions with proteins may be 
additional determinant of enhanced cytotoxicity of 
complex 2 in comparison to 1. 
On the other side, meta-position of the acetyl 
substituent on the pyridine ring (3-acetylpyridine) 
in complex 1, allowed reactivity with intracellular 
DNA and proteins, though in reversible manner.
Complex 1 platinum levels in cellular DNA de-
creased from 6 h to 24 h time points, indicating that 
1 treated cells partially recovered from the initial 
cytotoxic stress, which may be due to an early 
DNA damage response and removal of the plati-
num-DNA lesions.13 
In order to evaluate role of DNA-damage re-
pair in mediating differences in cytotoxicity of the 
tested complexes, we further evaluated expression 
of ERCC1 on mRNA and protein level. Nucleotide 
excision repair is one of the DNA-repair mecha-
nisms primarily activated in response to cisplatin 
induced genotoxic stress.39-42 In the case of CDDP, 
cycle cycle arrest in the phase G0/G1 (also caused 
by investigated complex 1) and G2/M arrest, may 
be indicative for activation of NER repair pro-
teins.20 Nevertheless, western blot and gene expres-
sion analysis in the current study, revealed reduc-
tion of ERCC1 mRNA and protein levels, following 
short-term treatment with 1 and 2, while there was 
discordance in mRNA and protein levels following 
CDDP treatment. It is likely that ERCC1 might not 
play fundamental role in mediating sensitivity to 
trans-platinum complexes, as well as to the inves-
tigated complexes in the current settings, but ad-
ditional studies need to be directed toward under-
standing of the molecular mechanism underlying 
expression status of ERCC1 (mRNA and protein), 
and its correlation to trans-platinum-based drug 
sensitivity.15,43
In the separate part of our study we investi-
gated the potential of tested complexes to modu-
late processes related to angiogenic and metastatic 
potential of tumor cells in vitro. Pathological an-
giogenesis is a hallmark of cancer and represents 
an important step in the development of metasta-
sis.44-46 Significant efforts in the area of anticancer 
drug research are focused on the development of a 
drug, which would be able to limitate angiogenesis 
of cancer cells. Study in MS1 cells revealed poten-
tial of 2 to inhibit formation of tube-like structures 
and tumor cell-cell contacts, at very low subtoxic 
concentration (0.03 IC50), while CDDP failed to 
show effect in this assay. Our results indicated po-
tential of complex 2 to act on multiple processes in 
cancer cells, and that exposure to DNA-damaging 
agents at subtoxic concentrations may alter tumor 
cell behavior. More direct experiments would be 
required to confirm the observed antiangiogenic 
potential of 2 in vitro. 
Matrix metalloproteinases 2 and 9, which are 
frequently over expressed in tumor cells, play a 
critical role in modulation of extra cellular matrix, 
and its role in tumor cell migration, formation of 
tumor cell contacts and angiogenesis transition is 
extensively investigated. Thus, MMPs represent 
a promising target for antitumor drug design.25,45 
Our investigations of the effect of tested complexes 
on gelatinolitic activity of secreted matrix metallo-
proteinases MMP-2 and MMP-9 and their mRNA 
expression levels, showed that both 1 and 2 caused 
decrease of MMP-9 mRNA, for 6 h action, though 
for the time point observed (6 h), inhibitory effect 
on the enzyme activity level was minor.44 Only 
complex 1 showed moderate inhibitory effect on 
MMP-2 and MMP-9 activity. Reduction of func-
tional levels of MMP-9 by 1 and 2 was in correla-
tion to the reduction of the enzyme mRNA-level, 
which might  represent the indirect effect of geno-
toxic stress.
Although two investigated complexes of struc-
tural formula trans-[PtCl2(n-acetylpyridine)2] (n 
= 3 or 4) represent close structural isomers, their 
interactions with cellular targets and consequently 
induced cellular responses are different. Results 
obtained suggest that structural settings play a 
fundamental role, since they are responsible for 
the interaction between trans-Pt drug and cellular 
DNA and proteins and the consequent biological 
effects. Higher cytotoxicity of 2 compared to the 1 
analogue, may be attributed to its ability to form 
different DNA-lesions, produce different cellular 
effects related to damage-precessing and signal ac-
tivation pathways, and induce multiple cellular re-
sponses. Our study demonstrated that complex 2 is 
particularly interesting since it exhibited cytotoxic 
and apoptotic potential in HeLa cells comparable 
to that of CDDP, though showing differences in 
terms of reactivity to DNA and proteins, cytoselec-
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tivity toward tumor cells and potential for in vitro 
angiogenesis inhibition. Further explorations are 
needed to determine a possible differential mecha-
nism of action and elucidate antitumor potential of 
complex in vivo. 
Altogether, properties of complexes of structur-
al formula trans-[PtCl2(n-acetylpyridine)2] (n = 3 or 
4), encourage further investigation of substituted 
trans-platinum pyridines in search for compound 
with different modalities of action toward cancer 
cells in comparison to CDDP.
Acknowledgements 
This work was supported by the Ministry of 
Science, Republic of Serbia, Grant, No.III 41026 and 
Grant, No 172017  (URL address: http://www.mpn.
gov.rs/sajt/).
References
1. O’Dwyer PJ, Stevenson JP, Johnson SW. Clinical status of cisplatin, carbo-
platin and other platinum-based antitumor drugs. In: Lippert B, editor. 
Cisplatin: chemistry and biochemistry of the leading anticancer drug. 
Weinheim, Germany: Wiley-VCH; 1999. p. 30-70. 
2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev 
Cancer 2007; 7: 573-84.
3. Desoize B, Madoulet C. Particular aspects of platinum compounds used 
at present in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 317-25.
4. Reedijk J. Metal-ligand exchange kinetics in platinum and ruthenium com-
plexes. Platinum Metals Rev 2008; 52: 2-11.
5. Wang, X. Fresh platinum complexes with promising antitumor activity. Anti-
Cancer Agents Med Chem 2010; 10: 396-411.
6. Farrell N, Kelland LR, Robert JD. Van Beusichem M. Activation of the trans 
geometry in platinum antitumor complexes: a survey of the cytotoxicity 
of trans complexes containing planar ligands in murine L1210 and human 
tumor panels and studies on their mechanism of action. Cancer Res 1992; 
52: 5065-72. 
7. Quiroga AG. Understanding trans platinum complexes as potential anti-
tumor drugs beyond targeting DNA. J Inorg Biochem 2012; 114: 106-12.
8. Coluccia M, Nassi A, Loseto F, Boccarell A, Mariggiò MA, Giordano D, et al. 
A trans-platinum complex showing higher antitumor activity than the cis 
congeners. J Med Chem 1993; 36: 510-2.
9. Radulović S, Tesić Ž, Manić, S. Trans-platinum complexes as anticancer 
drugs: recent developments and future prospects. Curr Med Chem 2002; 
9: 1611-8.
10. Pérez JM, Montero EI, González AM, Solans X, Font-Bardia M, Fuertes MA, 
et al. X-Ray structure of cytotoxic trans-[PtCl(2)(dimethylamine)(isopro-
pylamine)]: interstrand cross-link efficiency, DNA sequence specificity, and 
inhibition of the B-Z transition. J Med Chem 2000; 43: 2411-8.
11. Arandjelović S, Tesić Ž, Juranić Z, Radulović S, Vrvić M,  Potkonjak B, et al. 
Antiproliferative activity of some cis-/trans-platinum(II) complexes on HeLa 
cells. J Exp Clin Cancer Res 2002; 21: 519-26.
12. Aris SM, Farrell N. Towards antitumor active trans-platinum compounds. 
Eur J Inorg Chem 2009; 10: 1293-302.
13. Wang, X. Fresh platinum complexes with promising antitumor activity. Anti-
Cancer Agents Med Chem 2010; 10: 396-411.
14. Cubo L, Quiroga AG, Zhang J, Thomas DS, Carnero A, Navarro-Ranninger C, 
et al. Influence of amine ligands on the aquation and cytotoxicity of trans-
diamine platinum(II) anticancer complexes. Dalton Trans 2009; 18: 3457-66.
15. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer 
Res 2005; 11: 6100-2.
16. Manić S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P. Mechanisms 
controlling sensitivity to platinum complexes: role of p53 and DNA mis-
match repair. Curr Cancer Drug Targets 2003; 3: 21-9.
17. Kalayda GV, Wagner CH, Jaehde U. Relevance of copper transporter 1 for 
cisplatin resistance in human ovarian carcinoma cells. J Inorg Biochem 
2012, 116: 1-10.
18. Sadler PJ. Protein recognition of platinated DNA. ChemBioChem 2009; 10: 
73-4.
19. Ravera M, Gabano E, Sardi M, Ermondi G, Caron G, McGlinchey MJ, 
et al. Synthesis, characterization, structure, molecular modeling studies 
and biological activity of sterically crowded Pt(II) complexes containing 
bis(imidazole) ligands. J Inorg Biochem 2011; 105: 400-9. 
20. Ramos-Lima FJ, Moneo V, Quiroga AG, Carnero A, Navarro-Ranninger C. 
The role of p53 in the cellular toxicity by active trans-platinum complexes 
containing isopropylamine and hydroxymethylpyridine. Eur J Med Chem 
2010; 45: 134-41.
21. Huq F, Yu JQ, Daghriri H, Beale P. Studies on activities, cell uptake and DNA 
binding of four trans-planaramineplatinum(II) complexes of the form: trans-
PtL(NH3)Cl2, where L=2-hydroxypyridine, imidazole, 3-hydroxypyridine and 
imidazo(1,2-alpha)pyridine. J Inorg Biochem 2004; 98: 1261-70.
22. Aris SM, Knott KM, Yang X, Gewirtz DA, Farrell NP. Modulation of transpla-
naramine platinum complex reactivity by systematic modification of carrier 
and leaving groups. Inorg Chim Acta 2009; 362: 929-34.
23. Rakić GM, Grgurić-Sipka S, Kaluderović GN, Gómez-Ruiz S, Bjelogrlić SK, 
Radulović SS, et al. Novel trans-dichloridoplatinum(II) complexes with 
3- and 4-acetylpyridine: Synthesis, characterization, DFT calculations and 
cytotoxicity. Eur J Med Chem 2009; 44: 1921-5. 
24. Kim KY, Jeong SY, Won J, Ryu PD, Nam MJ. Induction of angiogenesis by 
expression of soluble type II transforming growth factor-beta receptor in 
mouse hepatoma. J Bio Chem 2001; 276: 38781-6.
25. Muscella A, Calabriso N, Vetrugno C, Urso L, Fanizzi FP, De Pascali SA, et 
al. Sublethal concentrations of the platinum(II) complex [Pt(O,O’-acac)
(gamma-acac)(DMS)] alter the motility and induce anoikis in MCF-7 cells. Br 
J Pharmacol 2010; 160: 1362-77.
26. Sasanelli R, Boccarelli A, Giordano D, Laforgia M, Arnesano F, Natile G, et 
al.Platinum complexes can inhibit matrix metalloproteinase activity: plati-
num-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors 
of matrix metalloproteinases 2, 3, 9, and 12. J Med Chem 2007; 50: 3434-41. 
27. Montiel M, Urso L, de la Blanca EP, Marsigliante S,  Jiménez E. Cisplatin 
reduces endothelial cell migration via regulation of type 2-matrix metal-
loproteinase activity. Cell Physiol Biochem 2009; 23: 441-8.
28. Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell desig-
nated MRC-5. Nature 1970; 227: 168-70.
29. Gligorijević N, Aranđelović S, Filipović L, Jakovljević K, Janković R, Grgurić-
Šipka S, et al. Picolinate ruthenium(II)-arene complex with in vitro an-
tiproliferative and antimetastatic properties: comparison to a series of 
ruthenium(II)-arene complexes with similar structure. J Inorg Biochem 
2012; 108: 53-61.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New 
colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer 
Inst 1990; 82: 1107-12.
31. Ormerod MG. Flow Cytometry, a Practical Approach. New York: Oxford 
University Press; 1994.
32. Bradford MM. A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding. Anal 
Biochem 1976; 72: 248-54.
33. Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the 
analysis of matrix metalloproteinases and their inhibitors. BioTechniques 
2005; 38: 73-83.
34. Musetti C, Nazarov AA, Farrell NP, Sissi C. DNA reactivity profile of trans-
platinum planar amine derivatives. Chem Med Chem 2011; 6: 1283-90.
Radiol Oncol 2013; 47(4): 346-357.
Filipovic L et al. / Biological evaluation of trans-Pt(II) complexes 357
35. Altaha R, Liang X,  Yu JJ,  Reed E. Excision repair cross complementing-group 
1: gene expression and platinum resistance. Int J Mol Med 2004; 14: 959-70.
36. Zorbas H, Keppler BK. Cisplatin damage: are DNA repair proteins saviors or 
traitors to the cell? Chem Bio Chem 2005; 6: 1157-66.
37. Ramos-Lima FJ, Vrána O, Quiroga AG, Navarro-Ranninger C, Halámiková 
A, Rybnícková H, et al. Structural characterization, DNA interactions, and 
cytotoxicity of new transplatin analogues containing one aliphatic and one 
planar heterocyclic amine ligand. J Med Chem 2006; 49: 2640-51.
38. Bierbach U, Sabat M, Farrell N. Inversion of the cis geometry requirement 
for cytotoxicity in structurally novel platinum(II) complexes containing the 
bidentate N,O-donor pyridin-2-yl-acetate. Inorg Chem 200; 39: 1882-90. 
39. Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J, et al. Differential 
contributory roles of nucleotide excision and homologous recombination 
repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol 
Cancer 2011; 10: 24.
40. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. 
Association between cisplatin resistance and mutation of p53 gene and 
reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 
56: 556-62.
41. Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor com-
pounds. Metallomics 2009; 1: 280-91. 
42. Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel 
S. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by 
siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer 
Res 2010; 30: 2531-8.
43. Kasparkova J, Marini V, Najajreh Y, Gibson D, Brabec V. DNA binding mode 
of the cis and trans geometries of new antitumor nonclassical platinum 
complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free 
media. Relations to their activity in cancer cell lines. Biochemistry 2003; 
42: 6321-32.
44. Arkell J, Jackson CJ. Constitutive secretion of MMP9 by early-passage cul-
tured human endothelial cells. Cel Biochem Funct 2003; 21: 381-6.
45. Ulukaya E, Ari F, Dimas K, Ikitimur KI, Yilmaz VT. Anti-cancer activity of a 
novel palladium(II) complex on human breast cancer cells in vitro and in 
vivo. Eur J Med Chem 2011; 46: 4957-63.
46. Kiran MS, Viji RI, Kumar SV, Prabhakaran AA, Sudhakaran PR. Changes in 
expression of VE-cadherin and MMPs in endothelial cells: Implications for 
angiogenesis. Vasc Cell 2011; 3: 6.
